There's an interesting Dutch article from January about how the rights ended up with this company [1]. It doesn't say anything about patents, but it does say (my translation):
> The producer (AAA, later bought by Novartis) gets exclusive rights to sell the drug, for ten years in the EU, and for seven in the US. The only exception is hospital pharmacies preparing the drug for their own patients.
I don't think journalistic language necessarily so accurate.
I don't think we can say for sure what changed hands in the transaction, but it should not matter anyhow.
If they bought everything, then the total lifetime value of the asset would hopefully have been baked into the price.